RT Journal Article
SR Electronic
T1 Importance of suppression and mitigation measures in managing COVID-19 outbreaks
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.03.31.20048835
DO 10.1101/2020.03.31.20048835
A1 Hochberg, Michael E.
YR 2020
UL http://medrxiv.org/content/early/2020/06/12/2020.03.31.20048835.abstract
AB I employ a simple mathematical model of an epidemic process to evaluate how four basic quantities: the reproduction number , the numbers of sensitive (S) and infectious individuals (I), and total community size (N) affect strategies to control COVID-19. Numerical simulations show that strict suppression measures at the beginning of an epidemic can create low infectious numbers, which thereafter can be managed by mitigation measures over longer periods to flatten the epidemic curve. The stronger the suppression measure, the faster it achieves the low numbers of infections that are conducive to subsequent management. Our results on short-term strategies point to either a two-step control strategy, following failed mitigation, that begins with suppression of the reproduction number, , below 1.0, followed by renewed mitigation measures that manage the epidemic by maintaining at approximately 1.0, or should suppression not be feasible, the progressive lowering of the effective reproductive number, , below 1.0. The objectives of the full sequence of measures observed in a number of countries, and likely to see in the longer term, can be symbolically represented as: . We discuss the predictions of this analysis and how it fits into longer-term sequences of measures, including misconceptions about ‘flattening the curve’ and how the herd immunity concept can be used to ‘leverage’ immunity.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo external funding was received.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data referred to in the manuscript is available upon request https://github.com/gabgoh/epcalc